Genialis

Kicking off #BioEuropeSpring in Milan and looking forward to great conversations on AI in drug development!

We’ve all heard it, AI is transforming the diagnosis and treatment of cancer But how is it 𝘢𝘤𝘵𝘶𝘢𝘭𝘭𝘺 being applied in real-world settings, and what challenges and opportunities does it bring? In a fireside chat, organized by Genialis and Slovenian Technology Forum (Slovenski tehnološki forum), Genialis’ co-founder and CEO Rafael Rosengarten and moderator Tjasa Zajc will talk just about that Event details:  📅 March 27, 2025, at 16.00 📍 Computer History Museum Slovenia 🔗 Register here: https://lnkd.in/dA6A9wTe  Join us! Limited seats available

I'm excited about the transformative potential of advanced AI tools—like those we're developing at Genialis—to address precision medicine’s blind spots and match novel therapies with the right patients faster 🚀 🚀 🚀

👉 What do you see as the biggest opportunity for AI in clinical development? How can we leverage digital advancements to bring new cancer medicines for patients? ✨Just wrapped up an insightful 3rd edition of our Digital Day here at Debiopharm. We delved into the transformative power of AI in Clinical Development and were fortunate to have an exceptional line-up of speakers who shared their expertise and insights on various topics - from the reality and future of AI in medicine, virtual twin experiences in Healthcare, to its role in R&D and personalized oncology. A special thank you to our guest speakers Daniel Truhn, Thomas Devenyns, Jean Colombel, Charlotte Bunne for their enlightening presentations👏. And a shout-out to our new Seed Fund investment companies: HopeAI, Raidium, Risklick, StratifAI and ViewsML Technologies.   As we continue this digital transformation journey in clinical development with AI at the forefront - we'd love to hear your thoughts.   Looking forward to continuing these conversations! #AI #ClinicalDevelopment #DigitalTransformation #VirtualTwins #AIinMedicine

Is AI truly transformative or merely a buzzword? Catch Genialis’ CTO Miha Stajdohar next week at BIO-Europe Spring, where he’ll share his take on this question. 💬 Panel discussion: The AI edit: What's the real deal? 📅 Tuesday, March 18 🕥 10:30 🤝 Michelle Chen (Insilico Medicine), Robert Grundy MBE (Intelligent OMICS Ltd), Friedrich von Bohlen (Molecular Health) See you in Milan! #BIOEuropeSpring EBD Group

After years in the shadows, KRAS mutations in colorectal cancer (CRC) are finally stepping into the therapeutic spotlight 💡 Once considered untouchable, this oncogene - altered in about 40% of advanced CRC cases - is now the focus of intense therapeutic development KRAS G12C inhibitors already made progress in lung cancer But since only ~3% of activating mutations in CRC are G12C, the therapeutic focus is shifting toward G12D and G12V, which are far more common in CRC 💪 Where is KRAS drug development for CRC headed today? 🔸 Allele-specific inhibitors, designed for the mutations that matter most in CRC, are now moving through clinical trials 🔸 Pan-KRAS and pan-RAS inhibitors are broadening treatment options for patients with less common variants 🔸 PROTAC degraders could go further by actively removing mutant KRAS, rather than just blocking its activity 🔸 T-cell receptor therapies and mRNA vaccines are offering new ways to mobilize the immune system against KRAS-mutant tumors KRAS in CRC is no longer out of reach The challenge now is making sure every patient gets the most appropriate treatment strategy Read the full article here: https://lnkd.in/dfuGBaFK

My thoughts on the latest St. Gallen Consortium assessment of R&D efficiency and drug approvals across large pharma. Drug development is long and wildly inefficient, benchmarking exercises like this are essential for the industry to quantify what is working and what isn't. I am excited to see the impact that AI tools (like what we are developing at Genialis) have on future efficiency assessments and how that translates to company value.

"Many told us integrating clinical data and diagnostics at scale 𝘄𝗮𝘀𝗻’𝘁 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲. But luckily, neither Eric nor I came from this industry, so we didn’t know any better. And that was our superpower." A decade later, Tempus AI has become a leader in AI-driven diagnostics, proving that its bold vision was not only possible but essential for the future of precision medicine We were thrilled to have Ryan Fukushima, COO of Tempus AI and CEO of Pathos, join the latest episode of Talking Precision Medicine 🎙️ Find the full episode here: https://lnkd.in/dM-xiZQS Hosted by Genialis' CEO, Rafael Rosengarten, this episode explores: 🔹 The origins of Tempus and how personal experiences with cancer shaped its mission 🔹 Why RNA data is critical for the future of precision medicine, despite initial skepticism from the pharmaceutical industry 🔹 How Pathos is tackling the phase two drug development bottleneck, using multimodal data to rescue promising therapies that might otherwise fail

"Synthetic data could revolutionize research by bypassing privacy barriers and enabling broader access to patient insights," says Luka Ausec, Chief Discovery officer at Genialis. When it comes to cancer, prevalence is increasing and there is still a lot we don't understand about the factors and causes of cancers. Globally, diagnoses and deaths related to early-onset cancers—those affecting patients younger than 50—rose by 79% and 28%, respectively, from 1990 to 2019, according to a recent study published in the medical journal BMJ Oncology. - https://lnkd.in/d4eEf3c5. I spoke with Luka to discuss the current state of cancer research, role of computational science in drug discovery, clinical decision support development and response predictions development in the field of cancer. Many studies have clearly demonstrated the benefits of biomarker testing for cancer therapy. However, broadly speaking, roughly 30% of cancer patients are eligible for targeted therapies based on their tumor profile. And even when the biomarket is present, roughly 30% of the eligible patients respond to these treatments. At Genialis, Luka oversees internal R&D and external partner projects, with the common goal of advancing therapeutic discovery through the rigorous application of data science. Our discussion topics include: 🎤 Challenges in matching patients to the right treatments 🎤 The limitations of current biomarker research and the need for complex models 🎤 The impact of diet and environmental factors on cancer treatment outcomes 🎤 Regulatory challenges in AI-driven drug development 🎤 The role of synthetic data and digital twins in cancer research 🎤 Ethical and economic considerations in healthcare resource allocation Tune in to the full discussion: YT: https://lnkd.in/dGera_U7 Spotify: https://lnkd.in/d_36rMj8 #cancer #biomarker #AI #computationalbiology